Clinical Trial

Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Exploring the efficacy and safety of zoledronic acid combined with neoadjuvant chemotherapy (EC-T) in neoadjuvant treatment for early-stage or locally advanced triple-negative breast cancer, the trial protocol of zoledronic acid + liposomal doxorubicin + cyclophosphamide followed by zoledronic acid + nab-paclitaxel will provide a new effective therapeutic strategy for neoadjuvant treatment of triple-negative breast cancer patients and offer a novel treatment approach for triple-negative breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-12.
Trial Details
NCT Number NCT06876636
Lead Sponsor Xijing Hospital
Conditions Breast Cancer Metastatic
Enrollment 99 participants
Start Date 2025-03-10
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-29